• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>WSEAS International Conferences >Prevention of relapses in the bipolar I disorder: a comparative study between quetiapine monotherapy vs. quetiapine-valproate combined therapy
【24h】

Prevention of relapses in the bipolar I disorder: a comparative study between quetiapine monotherapy vs. quetiapine-valproate combined therapy

机译：预防双极I紊乱中的复发：喹硫代单药治疗的比较研究与喹硫氨酸 - 戊醛组合治疗

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Although bipolar disorder is one of the most devastating of all psychiatric disorders in terms of risk for suicide, need for hospitalization, and suffering, the available pharmacologic agents for its treatment, until relatively recently, have been quite limited. Although some estimates suggest that the lifetime prevalence of bipolar disorder in the world wide is between 1% and 1.5%, this rate would be higher if patients with bipolar spectrum disorders beyond bipolar I and II disorder were included. The public health importance of this disease is heightened by the high rate of suicides and the high economic toll it can take, including lost work days and cost of care, as well as poor financial decision-making characteristics of the manic phase of the illnes We tried to evaluate whether quetiapine monotherapy reduces the rate of relapse, compared with combined therapy quetiqpine-valproate in patients with bipolar I disorder.
机译：虽然双极性障碍是在自杀风险方面是所有精神病患者最毁灭性的，但需要住院和痛苦，可用的药理剂进行治疗，直至相对最近，已相当有限。虽然一些估计表明，全球双相障碍的寿命患病率均在1％和1.5％之间，如果患有除了双极I和II疾病之外的双极谱紊乱的患者，这种速率会更高。这种疾病的公共卫生重要性提高了自杀的高速度和它可以采取的高度经济损失，包括失去工作日和护理成本，以及伊利恩斯躁狂阶段的财务决策特征差试图评估喹啉单疗法是否降低复发速率，与双极I紊乱患者的Quetiqpine-valproate相比。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号